Search

Displaying results 2031 - 2040 of 4588 in total
  1. Drug

    Pipamperone

    go.drugbank.com/drugs/DB09286
    Investigational

    It was developed by Janssen Pharmaceutica in 1961 and started its first round of clinical trials in 1963 [L1514, L1518].

  2. Drug

    Afamelanotide

    go.drugbank.com/drugs/DB04931
    Approved

    [L9086] It differs structurally from its endogenous counterpart by only two amino acids - these structural differences improve biological efficacy by imparting a greater affinity for its target and a longer

  3. Drug

    Glutathione disulfide

    go.drugbank.com/drugs/DB03310
    Approved

    A GLUTATHIONE dimer formed by a disulfide bond between the cysteine sulfhydryl side chains during the course of being oxidized.

  4. Drug

    Methadone

    go.drugbank.com/drugs/DB00333
    ApprovedInvestigational

    [A497,A5344] Specifically by inhibiting the NMDA receptor, methadone dampens a major excitatory pain pathway within the central nervous system. … Use of OAT is also intended to lead to social stabilization by reducing crime rates, incarceration, use of illicit opioids such as [heroin] or [fentanyl], and ultimately marginalization.

    Categories: High-risk opioids
  5. Drug

    Teprasiran

    go.drugbank.com/drugs/DB15064
    Investigational

    Teprasiran is under investigation in clinical trial NCT03510897 (QPI-1002 Phase 3 for Prevention of Major Adverse Kidney Events (MAKE) in Subjects at High Risk for AKI Following Cardiac Surgery).

  6. Drug

    Zenocutuzumab

    go.drugbank.com/drugs/DB15559
    ApprovedInvestigational

    [L51983] In May 2026, zenocutuzumab was granted additional approval by the US FDA for use in NRG1-positive cholangiocarcinoma. … [L51963] It works to attenuate aberrant cancer cell growth caused by genomic rearrangements involving the neuregulin 1 gene (NRG1), which is an oncogenic driver.

  7. Drug

    Methyldopa

    go.drugbank.com/drugs/DB00968
    ApprovedInvestigational

    Methyldopa works by binding to alpha(α)-2 adrenergic receptors as an agonist, leading to the inhibition of adrenergic neuronal outflow and reduction of vasoconstrictor adrenergic signals. … Since then, methyldopa was largely replaced by newer, better-tolerated antihypertensive agents;[A231784] however, it is still used as monotherapy [L32614] or in combination with [hydrochlorothiazide].

  8. Drug

    Danaparoid

    go.drugbank.com/drugs/DB06754
    ApprovedWithdrawn

    While it was initially approved by the FDA as Orgaran™, danaparoid was withdrawn by Organon International on August 14, 2002, due to a shortage in drug substance by the manufacturer. … Danaparoid possesses a potent antithrombic activity that works by inhibiting activated factor X (Factor Xa) and activated factor II (Factor IIa).

  9. Drug

    Erdafitinib

    go.drugbank.com/drugs/DB12147
    ApprovedInvestigational

    In early April of 2019, the US FDA approved Janssen Pharmaceutical Companies' brand name Balversa (erdafitinib) as the first-ever fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for patients with locally advanced or m...

  10. Drug

    Epinastine

    go.drugbank.com/drugs/DB00751
    Approved

    It has a multi-action effect that inhibits the allergic response in 3 ways: 1. stabilizes mast cells by preventing mast cell degranulation to control the allergic response, 2. prevents histamine binding